Last quarter (Q4 2022), APONTIS PHARMA AG's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, APONTIS PHARMA AG's net income was €―. See APONTIS PHARMA AG’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 55.73M	€ 51.18M	€ 39.24M	€ 40.04M	€ 11.73M
Cost of Revenue	-	€ 20.74M	€ 17.40M	€ 14.22M	€ 11.06M	€ 3.69M
Gross Profit	-	€ 34.99M	€ 33.79M	€ 25.03M	€ 28.97M	€ 8.05M
Operating Expense	-	€ 31.18M	€ 32.12M	€ 25.64M	€ 31.21M	€ 7.41M
Operating Income	-	€ 3.81M	€ 1.67M	€ -614.40K	€ -2.24M	€ 640.58K
Net Non Operating Interest Income Expense	-	€ 15.91K	€ -401.35K	€ -863.03K	€ -827.77K	€ -218.98K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	€ 3.83M	€ 248.26K	€ -1.48M	€ -3.07M	€ 421.61K
Tax Provision	-	€ 1.14M	€ 993.53K	€ -294.73K	€ -678.00K	€ 165.22K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ 2.69M	€ -745.24K	€ -1.18M	€ -2.39M	€ 256.55K
Basic EPS	-	€ 0.32	€ -0.09	€ -0.14	€ -0.28	€ 0.03
Diluted EPS	-	€ 0.32	€ -0.09	€ -0.14	€ -0.28	€ 0.03
Basic Average Shares	-	€ 8.50M	€ 8.50M	€ 8.50M	€ 8.50M	€ 8.50M
Diluted Average Shares	-	€ 8.50M	€ 8.50M	€ 8.50M	€ 8.50M	€ 8.50M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	€ 51.91M	€ 49.52M	€ 39.85M	€ 42.28M	€ 11.09M
Net Income From Continuing And Discontinued Operation	-	€ 2.69M	€ -745.24K	€ -1.18M	€ -2.39M	€ 256.55K
Normalized Income	-	€ 2.69M	€ -33.34K	€ -1.18M	€ -2.39M	€ 256.55K
Interest Expense	-	€ 48.00K	€ 406.00K	€ 868.00K	€ 828.00K	€ 215.00K
EBIT	-	€ 3.88M	€ 654.26K	€ -609.42K	€ -2.24M	€ 636.61K
EBITDA	-	€ 5.67M	€ 2.40M	€ 1.04M	€ -1.67M	€ 701.61K

Currency in EUR

APONTIS PHARMA AG Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing